1.Late but effective long-term response to splenectomy in the treatment of immune thrombocytopenia.
Laura SCARAMUCCI ; Marco GIOVANNINI ; Andrea TENDAS ; Pasquale NISCOLA ; Paolo DE FABRITIIS
Blood Research 2013;48(4):297-298
No abstract available.
Splenectomy*
;
Thrombocytopenia*
2.Primary mixed-type autoimmune hemolytic anemia concomitant with acute splanchnic venous thrombosis of idiopathic origin in a young woman: an unexplained association.
Laura SCARAMUCCI ; Marco GIOVANNINI ; Pasquale NISCOLA ; Alessio PERROTTI ; Paolo DE FABRITIIS
Blood Research 2013;48(4):292-293
No abstract available.
Anemia, Hemolytic, Autoimmune*
;
Female
;
Humans
;
Venous Thrombosis*
3.Acute myeloid leukemia arising from chronic myelomonocytic leukemia during hypomethylating therapy.
Pasquale NISCOLA ; Andrea TENDAS ; Laura SCARAMUCCI ; Marco GIOVANNINI ; Daniela PICCIONI ; Paolo DE FABRITIIS
Blood Research 2014;49(1):65-66
No abstract available.
Leukemia, Myeloid, Acute*
;
Leukemia, Myelomonocytic, Chronic*
4.Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab.
Andrea TENDAS ; Pasquale NISCOLA ; Laura SCARAMUCCI ; Luca CUPELLI ; Alessio Pio PERROTTI ; Paolo DE FABRITIIS
Blood Research 2016;51(2):137-138
No abstract available.
Red-Cell Aplasia, Pure*
;
Rituximab*
5.Evolution of chronic myelomonocytic leukemia from refractory anemia: the unusual course of a myelodysplastic syndrome.
Pasquale NISCOLA ; Andrea TENDAS ; Laura SCARAMUCCI ; Marco GIOVANNINI ; Stefano FRATONI ; Paolo DE FABRITIIS
Blood Research 2013;48(2):152-153
No abstract available.
Leukemia, Myelomonocytic, Chronic
;
Myelodysplastic Syndromes
6.Long-term hematological response in a patient with 5q- syndrome after suspension of lenalidomide therapy and further improvement with deferasirox therapy.
Pasquale NISCOLA ; Andrea TENDAS ; Laura SCARAMUCCI ; Roberta MEROLA ; Gianfranco CATALANO ; Paolo DE FABRITIIS
Blood Research 2014;49(2):130-137
No abstract available.
Humans
7.Concomitant transformation of monoclonal gammopathy of undetermined significance to multiple myeloma and of essential thrombocythemia to acute biphenotypic leukemia 37 years after initial diagnosis.
Pasquale NISCOLA ; Gianfranco CATALANO ; Stefano FRATONI ; Laura SCARAMUCCI ; Paolo DE FABRITIIS ; Tommaso CARAVITA
Blood Research 2013;48(3):228-230
No abstract available.
Leukemia, Biphenotypic, Acute
;
Monoclonal Gammopathy of Undetermined Significance
;
Multiple Myeloma
;
Paraproteinemias
;
Thrombocythemia, Essential
8.Successful re-treatment with azacitidine in a patient with low blast count AML transformed from MDS after suspension of this agent.
Pasquale NISCOLA ; Andrea TENDAS ; Laura SCARAMUCCI ; Marco GIOVANNINI ; Stefano FRATONI ; Paolo DE FABRITIIS
Blood Research 2015;50(2):113-114
No abstract available.
Azacitidine*
;
Humans
9.Steroid-refractory immune thrombocytopenia in the era of the new thrombomimetic drugs: is there still a role for rituximab?.
Massimiliano PALOMBI ; Laura SCARAMUCCI ; Marco GIOVANNINI ; Malgorzata Monika TRAWINSKA ; Pasquale NISCOLA ; Paolo DE FABRITIIS
Blood Research 2016;51(1):66-66
No abstract available.
Thrombocytopenia*
;
Rituximab
10.Regaining the response to erythropoietin following azacitidine in chronic myelomonocytic leukemia previously evolved from refractory anemia.
Pasquale NISCOLA ; Andrea TENDAS ; Roberta MEROLA ; Giulia ORLANDI ; Laura SCARAMUCCI ; Paolo DE FABRITIIS
Blood Research 2015;50(3):181-182
No abstract available.
Anemia, Refractory*
;
Azacitidine*
;
Erythropoietin*
;
Leukemia, Myelomonocytic, Chronic*
Result Analysis
Print
Save
E-mail